Go Deep
TScan Therapeutics, Inc.
TScan Therapeutics, Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 22,240 | -0.2 | 0.21 | 1.32 | 20.00 |
| Oct 2026 | 22,170 | -0.3 | 0.23 | 1.32 | 22.72 |
| Oct 2026 | 22,190 | -0.3 | 0.23 | 1.32 | 21.88 |
| Oct 2026 | 20,438 | -0.2 | 0.21 | 1.32 | 19.93 |
| Oct 2026 | 20,402 | -0.2 | 0.22 | 1.32 | 21.24 |
| Oct 2026 | 20,382 | -0.2 | 0.22 | 1.32 | 21.19 |
| Oct 2026 | 20,402 | -0.2 | 0.21 | 1.32 | 20.41 |
TScan Therapeutics, Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 1,051,000.0 | 982,000.0 | 2,567,000.0 | 2,511,000.0 |
| Net Profit | -30,359,000.0 | -28,666,000.0 | -22,977,000.0 | -35,710,000.0 |
| EPS | -0.2 | -0.2 | -0.2 | -0.3 |
TScan Therapeutics, Inc. Revenue & Profit: Last 5 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Revenue | 10,325,000.0 | 2,816,000.0 | 21,049,000.0 | 13,535,000.0 | — |
| Net Profit | -129,766,000.0 | -127,499,000.0 | -89,218,000.0 | -66,221,000.0 | — |
| EPS | -1.0 | -1.1 | -1.4 | -2.8 | — |
TScan Therapeutics, Inc. Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Total Assets | 228,789,000.0 | 371,118,000.0 | 272,149,000.0 | 199,091,000.0 | — |
| Total Liabilities | 105,666,000.0 | 130,148,000.0 | 121,282,000.0 | 99,657,000.0 | — |
| Total Equity | 123,123,000.0 | 240,970,000.0 | 150,867,000.0 | 99,434,000.0 | — |
Owes vs Owns
TScan Therapeutics, Inc. owed $0.60 for every $1 it owned in Jun 2026, up from $0.50 in Dec 2022.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 0.60× | 0.46× | 0.35× | 0.45× | 0.50× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
TScan Therapeutics, Inc. Assets & Liabilities Breakdown (USD millions)
What it owns — Dec 2025
Cash & short-term investments 66.6%Fixed assets (tangible) 29.0%Other assets 4.3%
How it's funded — Dec 2025
Short-term debt 3.1%Long-term debt 14.2%Payables 0.5%Other liabilities 28.3%Shareholders' equity 53.8%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 152.4 | 290.1 | 192.0 | 120.0 |
| Receivables | 0.0 | 0.0 | 0.0 | 0.0 |
| Inventory | 0.0 | 0.0 | 0.0 | 0.0 |
| Fixed assets (tangible) | 66.4 | 71.6 | 71.2 | 69.2 |
| Intangible assets | 0.0 | 0.0 | 0.0 | 0.0 |
| Long-term investments | 0.0 | 0.0 | 0.0 | 0.0 |
| Other assets | 9.9 | 9.4 | 8.9 | 9.9 |
| Liabilities & equity | ||||
| Short-term debt | 7.2 | 4.6 | 3.3 | 3.7 |
| Long-term debt | 32.5 | 32.1 | 26.7 | 29.3 |
| Payables | 1.2 | 4.3 | 2.4 | 2.9 |
| Other liabilities | 64.7 | 89.2 | 88.9 | 63.8 |
| Shareholders' equity | 123.1 | 241.0 | 150.9 | 99.4 |
| Net tangible assets | 123.1 | 241.0 | 150.9 | 99.4 |
TScan Therapeutics, Inc. Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Operating Activities | -135,319,000.0 | -110,822,000.0 | -61,358,000.0 | -66,503,000.0 | — |
| Investing Activities | 109,372,000.0 | -52,613,000.0 | -60,759,000.0 | -4,225,000.0 | — |
| Financing Activities | -336,000.0 | 208,765,000.0 | 135,443,000.0 | 29,356,000.0 | — |